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Summary 
The effect of interleukin 8 (I1,8) on I1,4-induced immunoglobulin  E (IgE) production was studied. 
I1,4 induced IgE and IgG4 production by tonsiUar mononuclear cells (MNC) without affecting 
IgM, IgG1, IgA, IgG2, or IgG3 production. IL-8 inhibited I1,4-induced IgE and IgG4 production, 
whereas it had no effect on IgM, IgG1, IgA, IgG2, and IgG3 production. The inhibitory effect 
by I1,8 was specific, since it was blocked by anti-I1,8 mAb, but not by control IgG1. Although 
interferon 3' (IFN-3')  also inhibited IgE and IgG4 production by MNC stimulated with I1,4, 
the inhibitory effect of I1,8 was not mediated by IFN-3', since the I1,8-induced inhibition could 
not be blocked by anti-IFN-3" mAb. Furthermore, anti-I1,8 mAb had no effect on IFN-3"-induced 
inhibition. Moreover,  addition of I1,5 or I1,6 did not reverse I1,8-induced inhibition of IgE 
production. In contrast to these observations with MNC, I1,4 failed to induce IgE and IgG4 
production by purified B cells. However, combined treatment of purified B cells with I1,4 and 
anti-CD40 antibody resulted in IgE but not IgG4 production. I1,8 inhibited this IgE production 
without affecting IgM, IgG1, IgG2, IgG3, IgG4, or IgA production, whereas IFN-3', IFN-c~, 
or prostaglandin E2  (PGE2) failed to  do so.  These results  indicate that I1,8 antagonizes I1, 
4-induced IgE production by directly affecting B cells through a specific mechanism that is different 
from IFN-3',  IFN-o~, or PGE2. 
I 
gE production has been shown to be regulated by many 
factors in various in vitro systems. In mononuclear cells 
(MNC), I1,4 induces IgE production, which can be inhibited 
by IFN-c~, IFN-3,, or prostaglandin E2 (PGE2) (1), and en- 
hanced by I1,5 or Ib6 (2, 3).  IL-4 has also been shown to 
inhibit IFN-3` synthesis or release of PGE2 (4, 5), indicating 
mutual interaction of these factors. In contrast, in purified 
B cells, I1,4 alone cannot induce IgE production. However, 
stimulation of purified B cells with I1,4 and anti-CD40 ab 
induces IgE production, which is IFN-a- and IFN-3`-inde- 
pendent (6-8). We have previously reported that soluble CD23 
enhances IgE production without affecting cell growth in 
the human IgE-producing cell line AF-10, which is a sub- 
clone of U266 (9). We have also found that IgE production 
is regulated by erythropoietin or disodium cromoglycate in 
an IFN-ol- and IFN-3`-independent, but in a T  cell- and 
monocyte-dependent fashion (10, 11). 
Ib8 was initially characterized  and cloned as a neutrophil 
chemotactic and activating agent (12). However,  it has sub- 
sequently been shown that I1,8 is also chemotactic for T cells, 
induces histamine release from I1,3-primed basophils,  and 
inhibits neutrophil adhesion to endothelium (13-15).  A re- 
port that I1,4 inhibits II,8 production from monocytes (16) 
prompted us to study the effect of I1,8 on I1,4-induced IgE 
production to see whether there was mutual interaction. We 
demonstrate that I1,8 inhibits IgE production in MNC and 
in purified B cells in an IFN-c~-  and IFN-3"-independent 
fashion. 
Materials and Methods 
Reagents.  The following recombinant human cytokines were 
kindly provided  by the companies as described  previously  (10, 11): 
IL-4 (Ono Pharmaceutical  Company, Osaka, Japan); Ib5 (Suntory 
Research Center, Osaka); IL-6 (kind gift from Drs. T. Hirano and 
T. Kishimoto,  Institute for Molecular  and Cellular  Biology,  Osaka); 
and IFN-c~ and IFN-3, (Takeda  Chemical  Industries,  Osaka). Human 
rib8 which has the same neutrophil-activating  potency as the nat- 
ural product isolated from LPS-stimulated  MNC and immunosor- 
bent purified mouse IgG1 monoclonal anti-IL-8 ab (4G9/AS/A7) 
were obtained from Sandoz Research Institute (Vienna, Austria) 
(12, 14). Chemotactic assay for fresh human neutrophils showed 
that activity was detected at 0.06-1.7 #g/m1, with maximal ac- 
tivity at 0.2 #g/ml. Mouse IgM anti-CD40 antibody  (MA6), mouse 
IgG3 anti-human IFN-3, ab and control mouse IgG1 were pur- 
chased from Cosmo Bio Co. (Tokyo,  Japan). PGE2 was purchased 
from Nakalai Chemicals (Kyoto, Japan). 
Cell Cultures.  TonsiUar  MNC from nonatopic donors were cul- 
tured (2  x  105/0.2 ml/well) in 96-well U-bottomed microtiter 
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medium (M. A. Bioproducts, Walkersville, MD) containing 10% 
FCS (Irvine  Scientific,  Santa Ana, CA), 2 mM t-glutamine,  50 U/ml 
penicillin, and 50/zg/ml streptomycin,  and stimulated with II.-4 
(800 U/ml) and various factors as described in Results. Highly 
purified B cells were obtained by SRBC rosetting, followed  by 
t-leucine methyl ester incubation as described previously (11). 
Purified B cell fractions contained, <1%  CD3 + T cells, <1% 
CD11 + monocytes,  <1% CD16  + NK cells, and >98% CD20  + B 
cells. Purified B cells were cultured (10  s cells/0.2 ml/weU) with 
various factors for 14 d. Control cultures for the evaluation of 
preformed Ig were carried out in the presence of cycloheximide 
(100/~g/ml). The amount of IgE, lgG subclasses, IgM, and lgA 
in the supernatants were determined by ELISA (9,  11). 
Results 
The effect of I1.8 on I1.4-induced IgE production was 
studied in MNC. As shown in Fig. 1 A, II-8 inhibited IgE 
production in a dose-dependent fashion. I1-,8 also inhibited 
IL,4-induced IgG4 production. In contrast, II-8 had no effect 
on IgM, IgG1, IgA, IgG2, and IgG3 production (Fig. 1 B). 
Ig production by MNC in the absence of II..4 were as follows: 
IgE <0.2 ng/ml; IgG1 705  _+  128 ng/ml; IgG2 217  +_  59 
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Figure 1.  Effect  of I1.-8 on Ig production by MNC stimulated with 
II.-4. MNC were stimulated with IL-4  (800 U/m1), and various concentra- 
tions of Ib8 were added. After 14 d of culture,  IgE and IgG4 (/1) and 
IgM, IgG1, IgA, IgG2 and IgG3 (B) were determined. Values are means 
+  one SD of triplicate cultures from two experiments. 
ng/ml; IgG3 108  _+ 25 ng/ml; IgG4 3.2 +_ 0.5 ng/ml; IgM 
910  __  129 ng/ml; and IgA 528  _+  91 ng/ml (mean +_  one 
SD from two experiments).  I1.8 did not affect production 
of these Igs in the absence of Ib4. 
We next studied the effect of delayed addition of IL-8 on 
I1.4-induced  IgE and IgG4 production. As shown in Fig. 
2, Ib8 inhibited IgE and IgG4 production only when added 
at the initiation of the 14-d cuhure. After 1 d of culture, 
II.-8 had no effect on IgE and IgG4 production. These results 
suggested that I1.8 interfered with IL-4 stimulation at the 
early stage, and that the inhibition  was not due to simple 
cytotoxic effects. 
Specificity of the I1.8 effect is documented in Table 1. In- 
hibition  of IgE and IgG4 production by II--8 was blocked 
by anti-IL,8 mAb, but not by control IgG1, although anti-IL-8 
did not affect IgE and IgG4 production in the absence of 
II.-8. IFN-~ also inhibited IgE and IgG4 production in I1-, 
4-stimulated cultures,  and  anti-IFN-y  mAb  completely 
blocked the inhibition by IFN-% However, inhibition by Ib8 
was not mediated by IFN-3,,  since the I1.8 effect was not 
blocked by anti-IFN-'y mAb, and conversely,  the IFN-'y effect 
was not blocked by anti-I1.8 mAb.  Moreover, addition of 
I1-,5 or II.-6 did not reverse I1.8-induced inhibition of IgE 
production (Table 1). 
We also studied the effect of I1-,8 on IgE production by 
purified B cells. It has been reported that stimulation of I1-,4 
and anti-CD40 ab induces IgE production by purified B cells 
in the absence ofT cells (6-8). Thus, highly purified B cells 
were stimulated with I1-,4 and anti-CD40 ab, and I1-,8 and/or 
other factors were added. As shown in Table 2, II+-8 had no 
effect on IgE, IgM, IgA, and IgG4 production by B cells 
without stimuli. Stimulation of II.,4 and anti-CD40 induced 
IgE but not IgM, IgA,  or IgG4 production. IgG1,  IgG2, 
or IgG3 production was also not induced (data not shown). 
Addition of IFN-a, IFN-3,,  or PGE2, which inhibits Ib4- 
induced IgE production by MNC (1), did not inhibit  IgE 
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Figure 2.  Kinetics of the addition of IL-8 to II.4-stimulated MNC. 
MNC were stimulated with IL-4  (800 U/ml), and IL-8 (1/zg/ml) was ~dd_M 
at the initiation (day 0), or after 1-4 days of culture. As controls, MNC 
were cultured with II.-4 (800 U/ml) in the absence of I1--8;  Ib8 (-). After 
14 d of culture,  IgE and IgG4 production were determined.  Values are 
means  +  one SD of triplicate cultures of IgE (@) and IgG4 (O). 
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Ig production 
Expt.  1  Expt.  2  Expt.  3 
Factors  IgE  IgG4  IgE  IgG4  IgE  IgG4 
ng/ml 
Medium  5.2  27.7  2.2  31.0  1.9  14.8 
IL-8  <0.2  3.0  0.6  2.1  <0.2  <0.6 
Anti-IL-8 mAb  6.2  31.2  3.0  40.4  2.7  17.2 
IL-8  +  anti-IL-8 mAb  4.9  25.2  2.0  25.8  1.6  12.0 
IL-8  +  control IgG1  <0.2  3.6  0.7  3.4  <0.2  0.5 
IL-8  +  anti-IFN-3, mAb  <0.2  4.2  0.9  3.5  <0.2  0.9 
IL-8  +  IL-5  <0.2  4.1  0.9  3.4  <0.2  0.8 
IL-8  +  IL-6  <0.2  4.5  1.0  3.2  <0.2  0.9 
IFN-~/  <0.2  2.6  0.3  1.0  <0.2  <0.6 
Anti-IFN-'y mAb  7.2  37.6  3.1  43.0  2.0  20.8 
IFN-3'  +  anti-IFN-3, mAb  5.0  30.1  1.9  30.0  1.6  12.9 
IFN-~/  +  anti-IL-8 mAb  <0.2  2.0  0.7  1.4  <0.2  0.6 
Tonsillar MNC were stimulated with IL-4 (800 U/ml), and cultured with indicated  factors. IL-8 was used at 1 #g/ml, anti-IL-8 mAb at 10 #g/ml, 
control IgG1 at 10/~g/ml, anti-IFN-'y at 10 I~g/ml, IL-5 at 100 ng/ml, IL-6 at 100 U/ml, and IFN at 1,000 U/ml. Values are means of triplicate 
cultures. SD were <15%. 
Table 2.  Effect of IL-8 on IgE and IgG4 Production by Purified B Cells Stimulated with IL-4 and Anti-CD40  Antibody 
Ig production 
Expt.  1  Expt.  2  Expt.  3 
Factors  IgE  IgM  IgE  IgA  IgE  IgG4 
Medium 
IL-8 
IL-4  +  anti-CD40 
IL-4  +  anti-CD40  +  IFN-'y 
IL-4  +  anti-CD40  +  IFN-c~ 
IL-4  +  anti-CD40  +  PGEz 
IL-4  +  anti-CD40  +  IL-8 
IL-4  +  anti-CD40  +  IL-8 
+  anti-IL-8 mAb 
IL-4  +  anti-CD40  +  IL-8 
+  control IgG1 
IL-4  +  anti-CD40  +  IL-8  +  IL-5 
IL-4  +  anti-CD40  +  IL-8  +  IL-6 
ng/ml 
<0.2  38.1  <0.2  5.0  <0.2  0.8 
<0.2  37.0  <0.2  4.4  <0.2  0.7 
3.1  ~.1  8.7  6.4  2.9  0.6 
3.3  32.3  8.5  5.2  2.5  0.7 
3.0  36.4  9.1  5.5  3.1  0.7 
2.8  40.9  8.2  5.9  3.0  0.8 
<0.2  41.2  0.5  5.6  0.7  0.7 
3.2  36.6  9.2  5.9  3.0  0.8 
<0.2  41.2  0.6  5.6  0.8  0.7 
<0.2  42.2  0.8  6.1  0.8  0.8 
<0.2  40.6  0.7  5.5  0.7  0.8 
Purified B cells were cultured with indicated factors. IL-8 was used at  1 /~g/ml, IL-4 at 800 U/ml, anti-CD 40 antibody at 0.1 /~g/ml, IFN-3' 
at 1,000 U/ml, IFN-r  at 1,000 U/ml, PGE2 at 10 -6 M, anti-IL-8 mAb at ~0/zg/ml,  control mouse IgG1 at 10/~g/ml,  IL-5 at 100 ng/ml, and 
IL-6 at 100 U/ml. Values are means of triplicate cultures. SD were <15%. 
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inhibited IgE production without affecting IgM, IgA, or IgG4 
production (Table 2). I1-8 also had no effect on IgG1, IgG2, 
or IgG3 production (data not shown). I1.8-induced inhibi- 
tion of IgE production was blocked by anti-I1.8 mAb, but 
not by control IgG1. Addition of I1.5 (up to 100 ng/ml) or 
I1.6 (up to 100 U/ml) did not reverse the I1.8-induced inhi- 
bition of IgE production. 
Discussion 
We have demonstrated that IL8  selectively inhibits IgE 
and IgG4 production in MNC stimulated with I1.4. Inhibi- 
tion by I1.8 was specific, since it could be blocked by anti-I1.8 
mAb but not by control mouse IgG1. Kinetic experiments 
showed that I1.8 had to be added at the initiation of the cul- 
ture. Delayed addition of Ib8  after 1 d  of culture had no 
effect. These results indicate that I1.8 inhibits the early acti- 
vation step during 11.4 stimulation, and that the inhibition 
is not due to cytotoxicity. Although IFN-3, also inhibited 
IgE and IgG4 production in those cultures, the I1.8 effect 
was not mediated by IFN-3,, since IbS-mediated inhibition 
was not blocked by anti-IFN-y mAb, and conversely,  the 
IFN-3, effect was not blocked by anti-I1.8 mAb. Moreover, 
I1.5 or IL-6, which enhanced I1.4-induced IgE production, 
did not reverse II.~8-induced inhibition of IgE production. 
Ib8  also  selectively inhibited IgE production by highly 
purified B cells stimulated with IL-4 and anti-CD40 antibody. 
In purified B cells, I1.8-induced inhibition of IgE produc- 
tion was specific and direct, since inhibition was not medi- 
ated through IFN-3,, IFN-ol, or PGE2,  which failed to in- 
hibit IgE production.  This is not surprising since they all 
inhibit I1.4-induced IgE production by MNC via interac- 
tions of T cells and B cells (1). Moreover, the I1.8 effect was 
blocked by anti-I1.8 mAb but not by control mouse IgG1, 
and was not reversed by I1.5 or I1.6. Taken together, these 
results indicate that 11.8 could inhibit I1.4-induced IgE pro- 
duction in both T cell-dependent and -independent systems, 
and the inhibition was not dependent on IFN-%  IFN-c~, 
IL-5, or I1.6. 
Monocyte-derived I1.8 has been characterized and cloned 
as a neutrophil chemotaxin and activator (12).  In addition 
to these activities,  Ib8 is chemotactic for T  cells (13), and 
induces histamine release by I1.3-primed basophils (14). I1.8 
mRNA can be induced in endothelial cells, fibroblasts,  epi- 
thelial cells, hepatoma cells, neutrophils, and T cells (17, 18). 
IL-8 receptors were detected on neutrophils, monocytes, tym- 
phocytes, T  cell and monoblast cell lines  (19, 20).  To our 
knowledge, this is the first report of a direct effect on B cells, 
resulting in inhibition of IgE production. Preliminary work 
in our laboratory showed that Ib8 also inhibits proliferation 
in human B cell line stimulated with IL-4 (Kimata et al., manu- 
script in preparation). 
The exact mechanism of the Ib8-induced inhibition of 
IgE production is currently under investigation. This system 
will be very useful to dissect the inhibition of IgE regula- 
tion. The in vivo role of I1.8 in IgE production remains to 
be elucidated. It has been reported that I1.5, Ib6, or IFN-T, 
which play an important role in IgE regulation in vitro, do 
not affect IgE regulation in vivo in atopic patients or in pa- 
tients with  hyper-IgE syndrome (21-23).  It might be in- 
teresting to assess Ib8 levels in those patients.  We are cur- 
rently studying the effect of II.,8 on IgE production by B 
cells from atopic patients. 
We wish to thank Dr. P. Peichl for production of, and M. Ceska for purification of, the anti-IL-8 mAb, 
and E. Wasserbauer for purification of II~8. 
This work was supported by a grant from the Ministry of Health and Welfare and a Grant-in-Aid for 
Scientific Research from the Ministry of Education, Science and Culture, Japan. 
Address correspondence to H. Kimata, Department of Pediatrics, Kyoto University, 54, Kawahara-cho, 
Shogoin, Sakyo-ku, Kyoto 606, Japan. 
Received for publication  II  May 1992 and in revised.form  18June  I992. 
References 
1.  l~ne, J., F. Rousset,  F. Bri&e, J. Chr&ine, J.-Y. Bonnefoy, 
H. Spits, T. Yokota, N. Arai, K. Arai, J. Banchereau, and J. 
De "Cries. 1988. IgE production by normal human lympho- 
cytes is induced by interleukin 4 and suppressed by interferon 
3' and c~ and prostaglandin E2. Proa Natl.  Acad. Sci. USA. 
85:6880. 
2.  P~ne,  J., E Rousset, F. Fri~re, I. Chr&ien, J. Wideman, J.-Y. 
Bonnefoy, andJ.E. De Vries. 1988. Interleukin 5 enhances in- 
terleukin 4-induced IgE production by normal human B cells. 
The role of soluble CD23  antigen. Eur. J. lmmunol.  18:929. 
3.  Vercelli,  D., H.H. Jabara, K. Arai, T. Yokota, and R.S. Geha. 
1989. Endogenous IIr6 plays an obligatory role in Ib4 induced 
human IgE synthesis. Fur. j. Immunol. 19:1419. 
4.  Vercelli,  D., H.H. Jabara, R.P. Lauener, and R.S. Geha. 1989. 
II.-4 inhibits the synthesis of IFN-3, and induces the synthesis 
of IgE  in  human mixed lymphocyte cultures. J.  Imraunol. 
144:570. 
5.  Hart, P.H., G.F. Vitti, D.R. Burgess, G.A. Whitty, D.S. PicoUi, 
1230  1I.,8 Inhibits Human Immunoglobulin  E Production and J.H. Hamilton. 1989. Potential antiinflammatory effects 
ofinterleukin 4: suppression  of  human monocyte  tumor necrosis 
factor or, interleukin 1, and prostaglandin E2. Proa Natl. Acad. 
Sci. USA.  86:3803. 
6. Jabara, H.H., S.M. Fu, K.S. Geha, and D. VerceUi. 1990. CD40 
and IgE: synergy between anti-CD40 monodonal antibody 
and interleukin 4 in the induction of IgE synthesis by highly 
purified human B cells.  J. Exp. Med.  172:1861. 
7.  Zhang, K., E.A. Clark, and A. Saxon. 1991. CD40 stimula- 
tion  provides an  IFN-7-independent  and  Ib4-dependent 
differentiation  signal directly to human B cells for IgE produc- 
tion. J. Immunol.  146:1836. 
8.  Gascan, H., J.-F. Gauchat, G. Aversa, P.E. Vlasselear, andJ.E. 
De "Cries. 1991. Anti-CD40 monoclonal antibodies or CD4 § 
T cell  clones  and Ib4 induce  IgG4 and IgE switching in purified 
human B cells via different signaling pathways.  J. Immunol. 
147:8. 
9.  Kimata, H., and A. Saxon. 1988. Subset of natural killer cells 
is induced by immune complexes to display Fc receptors for 
IgE and IgA and demonstrate isotype regulatory function. J. 
Clin. Invest. 82:160. 
10.  Kimata, H., A. Yoshida, C. Ishioka, and H. Mikawa. 1991. 
Effect of recombinant human erythropoietin on human IgE 
production in vitro.  Clin. Exp. Immunol.  83:483. 
11.  Kimata, H., A. Yoshida, C. Ishioka, and H. Mikawa. 1991. 
Disodium  cromoglycate  (DSCG) selectively inhibits  IgE 
production and enhances IgG4 production by human B cells 
in vitro.  Clin. Exp.  Immunol.  84:395. 
12.  Lindley,  I., H. Aschauer,  J.-M. Seifert,  C. ]_am, W. Brunowsky, 
E.  Kownatzki,  M.  Thelen,  P.  Peveri, B.  Dewalo, V.  Von 
Tscharner, et al. 1988. Synthesis and expression in Escherichia 
coli  of  the  gene encoding  monocyte-derived neutrophil- 
activating factor: biological equivalence between natural and 
recombinant neutrophil-activating factor. Proc. Natl. Acad. Sci. 
USA.  85:9199. 
13.  Larsen, C.G., A.O. Anderson, E. Appella, J.J. Oppenheim, 
and K. Matsushima. 1989. The neutrophil-activating protein 
(NAP-l) is also chemotactic for T lymphocytes.  Science (Wash. 
DC). 243:1464. 
14.  Dahinden, C.A., Y. Kurimoto, A.L. De Weck, I. Lindley, B. 
Dewald, and M. Baggiolini. 1989. The neutrophil-activating 
peptide NAF/NAP-1 induces  histamine release and leukotriene 
release by interleuldn 3-primed basophils.J. Ex~ Mea~ 170:1787. 
15.  Gimbrone, Jr., M.A., M.S. Obin, A.F. Brock, E.A. Luis, P.E. 
Hass, C.A. H6bert, Y.K. Yip, D.W. Leung, D.G. Lowe, W.J. 
Kohr, et al. 1989. Endothelial interleukin-8: a novel inhibitor 
of leukocyte-endothelial interactions.  Science (Wash. DC). 
246:1601. 
16.  Standiford, T.J., IL.M. Stricter, S.W. Chensue, J. Westwick, 
K. Kasahara, and S.L. Kunkel. 1990. IL4 inhibits the expres- 
sion of IL-8 from stimulated human monocytes.  J. lmmunol. 
145:1439. 
17.  Baggiolini, M., and S.L. Kunkel. 1989. Neutrophil-activating 
peptide-1/interleukin 8, a novel cytokine that activates neu- 
trophils. J.  Clin. Invest. 84:1045. 
18.  Kunkel,  S.L., lL.M. Streiter, S.W. Chensue, M.A. Basha, T.J. 
Standiford, J. Ham, and D.G. Remick. 1990. Tumor necrosis 
factor-alpha, interleukin-8  and  chemotactic  cytokines. In 
Cytokines and Lipocortins in Inflammation and Differentia- 
tion. M. Melli, and L. Parente, editors. Alan  lL. Liss Inc., New 
York. pg. 433. 
19.  Besemer,  J., A. Hujber, and B. Kuhn. 1989. Specific  binding, 
internalization, and degradation  of human neutrophil activating 
factor  by human polymorphoneucleat  leukocytes.J.  Biol. Chem. 
264:17409. 
20.  Grob, P.M., E. David, T.C. Warren, R.P. DeLeon, P.R. Fa- 
rina, and C.A.  Homon. Characterization of a receptor for 
human monocyte-derived  neutrophil chemotactic factor/inter- 
leukin-8. J. Biol. Chem.  265:8311. 
21.  Vercelli, D.,  H.H.  Jabara, C.  Cunningham-lLundles, J.S. 
Abrams, D.B. Lewis,  J. Meyer,  L.C. Schneider,  D.Y.M. Leung, 
and R.S. Geha. 1991. Regulation of immunoglobulin (Ig)E 
synthesis in the hyper-IgE syndrome.  J. Clin. Invest. 85:1666. 
22.  Lebedin, Y.S., L.A. Raudla, and A.G. Chuchalin. 1991. Serum 
levels ofinterleukin 4, interleukin 6 and interferon-gamma  fol- 
lowing in vivo isotype-specific  activation of IgE synthesis in 
humans. Int. Arch. Allergy. Appl.  Immunol.  96:92. 
23.  Classen,  J.J., A.D. Levine,  S.E. Schiff,  and R.H. Buckley. 1991. 
Mononuclear cells from patients with the hyper-IgE syndrome 
produce little IgE when they are stimulated with recombinant 
human interleukin-4. J. Allergy. Clin.  Immunol. 88:713. 
1231  Kimata  et al.  Brief  Definitive Report 